
Pembrolizumab Plus Concurrent Chemoradiation Represents New SOC for High-Risk, Locally Advanced Cervical Cancer
Findings from the phase 3 KEYNOTE-A18 trial (NCT04221945) showed that adding pembrolizumab (Keytruda) to concurrent chemoradiotherapy improved overall survival (OS) and time to second disease progression or death (PFS2) without introducing new safety …